Adapting the GLP-1-Signaling System to the Treatment of Type 2 Diabetes

Title: Adapting the GLP-1-Signaling System to the Treatment of Type 2 Diabetes

Volume: 3 Issue: 1

Author(s): Teresa Salvatore, Ornella Carbonara, Domenico Cozzolino, Roberto Torella and Ferdinando Carlo Sasso

Affiliation:

Keywords: Incretin effect, Glucagon-like peptide-1, Type 2 diabetes, GLP-1R agonists, DPP-IV inhibitors

Abstract: Glucagon-like peptide-1 (GLP-1) may contribute to the decreased incretin effect characterizing type 2 diabetes. Multiple actions other than insulin secretion stimulation give to GLP-1 a highly desirable profile for an antidiabetic agent. To overcome the need for continuous infusion of the native compound, which is rapidly degraded by dimetyl peptidil peptidase-IV (DPP-IV), analogues with low affinity for this protease have been developed. A second major strategy is represented by DPP-IV inhibitors that act to increase endogenous GLP-1. On the basis of the promising results in clinical trials, the incretin-based therapy may offer an useful option for diabetes management.

Cite this article as:

Salvatore Teresa, Carbonara Ornella, Cozzolino Domenico, Torella Roberto and Carlo Sasso Ferdinando, Adapting the GLP-1-Signaling System to the Treatment of Type 2 Diabetes, Current Diabetes Reviews 2007; 3 (1) . https://dx.doi.org/10.2174/157339907779802076